BAYER: RDOS. 3T’24 (ANÁLISIS BANCO SABADELL)
Rdos. 3T'24 vs 3T'23:Ventas: 9.968 M euros (-3,6% vs -1,7% BS(e) y -2,2% consenso);
EBITDA: 1.251 M euros (-25,8% vs -18,0% BS(e) y -22,1% consenso).
Rdos. 9meses'24 vs 9meses'23:
Ventas: 34.877 M euros (-2,5% vs -2,0% BS(e) y -2,1% consenso);
EBITDA: 7.774 M euros (-10,5% vs -9,0% BS(e) y -9,8% consenso).
Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.